Anti-TMPRSS6 Monoclonal Antibodies and Therapeutic Uses
Summary
USPTO published patent application US20260098084A1 disclosing fully human anti-TMPRSS6 monoclonal antibodies for treating diseases associated with TMPRSS6. Inventors include Harvey Chin, Sarah J. Hatsell, Heinrich Emil Lob, Andrew J. Murphy, William Olson, Kei Saotome, and Bojie Zhang, with application number 19323318 filed September 9, 2025.
What changed
USPTO published patent application US20260098084A1 covering fully human monoclonal antibodies binding to transmembrane serine protease 6 (TMPRSS6) and methods of use for treating associated diseases. The application claims antibodies useful in therapeutic applications for TMPRSS6-related conditions.
For pharmaceutical companies and biotechnology firms developing treatments targeting TMPRSS6, this publication establishes prior art and may impact freedom-to-operate analyses. Competitors should review the claims scope to assess potential licensing needs or design-around strategies for their own TMPRSS6-targeted therapeutic programs.
What to do next
- Monitor for patent prosecution updates
- Conduct freedom-to-operate analysis if developing TMPRSS6-targeted therapies
- Review claims for potential licensing opportunities
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF
Application US20260098084A1 Kind: A1 Apr 09, 2026
Inventors
Harvey CHIN, Sarah J. HATSELL, Heinrich Emil LOB, Andrew J. MURPHY, William OLSON, Kei SAOTOME, Bojie ZHANG
Abstract
Provided herein are monoclonal antibodies that bind to the transmembrane serine protease 6 (TMPRSS6) protein, and methods of use thereof. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to TMPRSS6. In some embodiments, the antibodies disclosed herein are useful in a method for treating or preventing a disease, disorder or condition associated with TMPRSS6 in humans.
CPC Classifications
C07K 16/18 A61P 1/16 A61K 2039/505 A61P 7/00 C07K 16/28 C07K 2317/565 C07K 2317/76 C07K 2317/92
Filing Date
2025-09-09
Application No.
19323318
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.